Difference between revisions of "Resource:F5e8362e-3dd6-4b95-a148-e0ccdb1cd4f3"
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
|Resource Type=Cases | |Resource Type=Cases | ||
|Title=The Olivieri Debacle: Where Were the Heroes of Bioethics? | |Title=The Olivieri Debacle: Where Were the Heroes of Bioethics? | ||
| − | |Is About=This is a factual case. | + | |Is About=This is a factual case about a blood researcher who is pressured by a pharmaceutical company into not sharing any details of a clinical trial which was terminated after the drug under investigation was suggested to be ineffective and maybe even harmful for the patients. The researcher received no support from the institution she was working for. The institution was later shown to have a conflict of interest. The article especially emphasizes the lack of action by the bioethical community in this case. |
<references /> | <references /> | ||
| − | |Important Because=<br /> | + | |Important Because=Publication of clinical trial results is important, especially if the drug under investigation is potentially harmful to the patients. If the pharmaceutical company tries to force the researcher to do otherwise, the institution should intervene and try to support its employee, even if this means that the institution receives no funding from the company. Similarly, the local bioethical community should offer support as well. The example at hand shows the potential consequences if this is not the case: the integrity of the research may be endangered, along with the health of both the patients and researchers. <br /> |
<references /> | <references /> | ||
| − | |Important For=Researchers | + | |Important For=Researchers; Research Ethics Committees; Universities; Academic staff; Academic institutions; Clinical researchers; Industry |
}} | }} | ||
{{Link | {{Link | ||
| Line 12: | Line 12: | ||
}} | }} | ||
{{Related To | {{Related To | ||
| − | |Related To Theme=Theme:9ac8c1db-f98b-41ee-858d-a8c93a647108 | + | |Related To Theme=Theme:9ac8c1db-f98b-41ee-858d-a8c93a647108;Theme:6d71bd59-c3bc-4cd5-9c9f-1ab4e53fc320;Theme:Fe62e07c-2e75-4a55-82e6-1908fa543b7a;Theme:0d054575-ca21-4209-b7c5-6120fc0ed647 |
}} | }} | ||
{{Tags | {{Tags | ||
|Has Timepoint=1995 | |Has Timepoint=1995 | ||
|Has Location=Canada | |Has Location=Canada | ||
| − | |Has Virtue And Value=Respect; Honesty | + | |Has Virtue And Value=Respect; Honesty; Transparency; Compassion; Collegiality; Safety |
|Has Good Practice And Misconduct=Informed consent; Conflict of interest; Patient safety | |Has Good Practice And Misconduct=Informed consent; Conflict of interest; Patient safety | ||
|Related To Research Area=Clinical Medicine | |Related To Research Area=Clinical Medicine | ||
}} | }} | ||
Latest revision as of 16:03, 19 August 2021
ResourcesThe Olivieri Debacle: Where Were the Heroes of Bioethics?
What is this about?
This is a factual case about a blood researcher who is pressured by a pharmaceutical company into not sharing any details of a clinical trial which was terminated after the drug under investigation was suggested to be ineffective and maybe even harmful for the patients. The researcher received no support from the institution she was working for. The institution was later shown to have a conflict of interest. The article especially emphasizes the lack of action by the bioethical community in this case.
Why is this important?
Publication of clinical trial results is important, especially if the drug under investigation is potentially harmful to the patients. If the pharmaceutical company tries to force the researcher to do otherwise, the institution should intervene and try to support its employee, even if this means that the institution receives no funding from the company. Similarly, the local bioethical community should offer support as well. The example at hand shows the potential consequences if this is not the case: the integrity of the research may be endangered, along with the health of both the patients and researchers.
